Arylomycin A2
Also known as: Arylomycin A-2, Arylomycin A₂
Summary
Arylomycin A2 is a naturally occurring lipoglycopeptide/lipopeptide antibiotic produced by Streptomyces sp. It is a prototype member of the arylomycin family and serves as a lead compound for the development of type I signal peptidase inhibitors as a novel antibacterial class. Its natural antimicrobial spectrum is narrow due to a resistance-conferring proline substitution (Pro29) in many bacterial species, but it has informed the design of optimized analogs with broader activity.
Mechanism of Action
Inhibits bacterial type I signal peptidase (SPase I, SpsB), an essential membrane-bound enzyme that cleaves signal peptides from secreted and membrane proteins, thereby blocking bacterial protein secretion and cell viability.
Routes of Administration
Goals & Uses
- Antibacterial activity against Gram-positive bacteriaAntimicrobialModerate
- Scaffold for antibiotic drug discoveryDrug DiscoveryModerate
- Target validation of type I signal peptidaseResearch ToolHigh
Contraindications
- Human use / clinical administrationRegulatoryHigh
Adverse Effects
- Cytotoxicity (in vitro)ToxicityUnknown
Drug Interactions
No drug interactions recorded yet.
Population Constraints
- General human populationRegulatory/safetyAbsolute
Regulatory Status
- European UnionUnapprovedNo regulatory filing or approval; research use only.
- United StatesUnapprovedResearch compound only; no IND or clinical development status for arylomycin A2 itself.
- United KingdomUnapprovedNo regulatory filing or approval; research use only.
No regulatory approvals in any jurisdiction. Arylomycin A2 is a research-stage natural product used as a tool compound and scaffold for drug discovery. Optimized analogs (e.g., G0775) have advanced into preclinical/early clinical investigation.
Evidence & Sources
No sources recorded yet.